Lack of correlation of the patientderived Vitiligo Disease Activity Index with the clinician-derived Vitiligo Area Scoring Index
To the Editor: Patients with vitiligo often have unpredictable, fluctuating periods of inactivity interspersed with periods of depigmentation. 1 The Vitiligo Disease Activity Index (VIDA) is an outcome measure used to determine disease activity in patients with vitiligo. 2 Unlike other disease activity scores in dermatology, the VIDA relies on patient recall. Although clinical signs of active disease such as confetti-like depigmentation, Koebner phenomenon, and trichrome depigmentation are predictors of disease activity, there is no activity score that incorporates these findings. [3] [4] [5] The VIDA score asks the patient to recall the last time they noted depigmentation during the past 12 months using a 6-point scale from e1 to 14, with higher scores indicating more recent disease activity. Our objective was to determine if patients are capable of accurately recalling their disease activity using the VIDA score.
We performed a retrospective, case-control study of VIDA scores for patients with vitiligo obtained at baseline and a follow-up visit 6 weeks to 6 months later. We used the temporal restrictions of the chosen VIDA scores and the clinician-derived Vitiligo Area Scoring Index (VASI) score as a method to determine the accuracy of the patient's VIDA score. The VASI score is used to determine the severity of depigmentation in patients with vitiligo. 6 Predetermined, written rules outlined the requirements for scores that were either consistent or inconsistent with the temporal window of the patient's chosen VIDA score and clinician-performed assessment of pigmentation (Table I) . These rules were applied to each follow-up VIDA score to determine whether the score was accurate. Inclusion criteria required a VIDA and VASI score documented at baseline and follow-up 6 weeks to 6 months later for subjects enrolled in the Dallas Vitiligo Registry at the University of Texas Southwestern Medical Center.
A total of 43 follow-up VIDA scores met inclusion criteria and were analyzed. A one-sample proportions test with a Yates correction for continuity was used to test the null hypothesis, which showed that the proportion of accurate follow-up VIDA scores was no different than that which would occur by chance. There were a total of 25 accurate scores and 19 inaccurate scores (58% scores correct). Our study failed to reject the null hypothesis that the percentage of accurate scores is no different from that which would occur by chance, ie, a patient's chance of accurately determining their own disease activity using the VIDA score is similar to flipping a coin.
These results demonstrate that the patientderived VIDA score does not correlate with disease activity as measured by change in VASI over time. Patients are not accurate in predicting their own disease activity using the VIDA, which is likely due to recall bias. Further studies to develop a clinical score reflecting signs of disease activity, such as confetti-like depigmentation, Koebner phenomenon, and trichrome depigmentation, should be performed. At baseline, the patient chose a VIDA of 4, indicating recent activity within the past 6 weeks, but at the 3 month followup visit, the patient chose a VIDA score of 0, indicating no activity in the past 12 months. 2. Increase in VIDA at follow-up cannot correspond with a decrease in VASI. Number of violations: 4
The patient chose a higher VIDA score at follow up compared with baseline, indicating worsening disease; however, the VASI score decreased, indicating improvement. 3. Increase in VIDA at follow-up cannot correspond with a stable VASI at follow-up unless the increase is from e1 to 0. Number of violations: 3
The patient gave a higher VIDA score at follow-up compared with baseline, indicating worsening disease; however, the VASI score did not change, indicating stable disease. 4. Decrease in VIDA at follow-up cannot correspond with an increase in VASI. Number of violations: 2
The patient had a lower VIDA at follow-up compared with baseline, indicating no new disease activity; however, the VASI score increased, indicating worsening disease. 5. Change in VIDA from 0 to À1 or vice versa cannot correspond with an increase in VASI.
Number of violations: 1
The patient had a decrease in VIDA from 0 to À1 at follow-up compared with baseline, indicating spontaneous repigmentation; however, the VASI score increased, indicating worsening disease. 6. When the VIDA and VASI are both unchanged, they must temporally correlate. Number of violations: 2
The patient reported a stable VIDA of 3, indicating active disease in the past 6 weeks to 3 months; however, the VASI score at 4 months follow-up did not change, indicating stable disease. 7. Change in VASI has to temporally correlate with any stable VIDA score. Number of violations: 5
The patient continued to report a VIDA of 1 at follow-up, indicating active disease in the past 6-12 months; however, the VASI score for this patient at 3-month follow-up increased, indicating active disease at 3 months, not 6-12 months.
VIDA, Vitiligo Disease Activity Index; VASI, Vitiligo Area Scoring Index.
